Pharmacological risk factor for gastrointestinal bleeding after endoscopic submucosal dissection in gastric cancer patients with direct oral anticoagulants

Pharmacological risk factor for gastrointestinal bleeding after endoscopic submucosal dissection in gastric cancer patients with direct oral anticoagulants - Pharmacological risk factor for bleeding after ESD in patients with DOAC

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000031930

Enrollment

400

Registered

2018-03-28

Start date

2018-03-27

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Early-stage gastric cancer patients treated with DOAC

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. With consent 2. Performance status: ECOG 0 or 1 3. Early stage gastric cancer according to the treatment guideline for gastric cancer by the Japanese association of gastric cancer. 4. Over 20 years old patients treated with DOAC

Exclusion criteria

Exclusion criteria: 1. No consent 2. with three kinds of anticoagulants 3. with severe diseases (heart, liver and pulmonary failure) 4. Pregnancy

Design outcomes

Primary

Measure	Time frame
Association with plasma concentration of DOAC at trough or anti-Xa activity and incidence of bleeding after ESD for early-stage gastric cancer in patients treated with DOAC	—

Countries

Japan

Contacts

Public ContactMitsushige Sugimoto

Shiga University of Medical Science Hospital Division of Digestive Endoscopy

sugimo@belle.shiga-med.ac.jp077-548-2618

Outcome results